Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug

by Vishnuprasad on  January 22, 2015 at 7:20 PM AIDS/HIV News
RSS Email Print This Page Comment
Font : A-A+

Indian pharmaceutical company Strides Arcolab has entered into a licensing agreement with US-based Gilead Sciences to manufacture and distribute latter's low-cost HIV drug, Tenofovir Alafenamide (TAF), in developing countries.
 Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug
Strides Arcolab Inks Deal With Gilead Sciences for HIV Drug

In a BSE filing, Strides Arcolab said, "It has entered into a licensing agreement with Gilead Sciences, Inc under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs."

Strides said that the license being granted to it extends to 112 countries.

"Strides will receive technology transfer from Gilead, enabling Strides to manufacture low cost versions of TAF for developing countries," the company stated.

TAF is an investigational product in the US and have not yet been determined safe and efficacious in humans.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive